Bladder Cancer | Tumor

Frontline Keytruda Shows Benefit Bladder Cancer

June 26th 2017

For patients with cisplatin-ineligible advanced urothelial cancer, frontline treatment with Keytruda (pembrolizumab) showed long-lasting response, according to updated phase 2 results from the KEYNOTE-052 trial.

Expert Discusses Urothelial Carcinoma's Newest Agent

June 20th 2017

Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.

Pre-Surgical Gemcitabine Plus Cisplatin Benefits Bladder Cancer

June 15th 2017

When used as a neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC), split-dose of gemcitabine and cisplatin has a beneficial response and a high safety profile, according to a study presented at the 2017 American Urological Association Annual Meeting.

Combined Modality Treatment May Be OK as First Course of Treatment for Muscle-Invasive Bladder Cancer

June 7th 2017

Combined modality treatment (CMT) could be considered a first course of treatment for patients with muscle-invasive bladder cancer, according to the authors of a recent study published in the International Journal of Radiation Oncology.

Drug Combination Is Effective in Urothelial Carcinoma

June 6th 2017

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.

Combination Improves Progression-Free Survival in Urothelial Carcinoma

June 1st 2017

According to results from the phase 3 RANGE trial, the addition of Cyramza (ramucirumab) to docetaxel resulted in improved progression-free survival for patients with previously treated locally advanced or unresectable or metastatic urothelial carcinoma.

Marilu Henner: Acknowledging Symptoms is the First Stop on the Road to Health

June 1st 2017

Actress Marilu Henner spoke with CURE about her husband's journey with cancer and the importance of having the difficult conversations.

Expert Discusses Reducing Recurrence Risk in Bladder Cancer

May 26th 2017

Edward Messing, M.D., discusses his recent paper which explored a possible way to reduce recurrence in some patients with bladder cancer.

Electronic Cigarettes May Still Pose Bladder Cancer Risk

May 24th 2017

Though deemed "safer" than normal cigarettes, electronic cigarettes may still pose a risk for bladder cancer.

Expert Discusses Urothelial Carcinoma Approval

May 23rd 2017

Arjun V. Balar, M.D., discusses Keytruda's impact on the treatment of urothelial carcinoma.

FDA Approves Keytruda Approved for Urothelial Carcinoma

May 18th 2017

Keytruda (pembrolizumab) was granted an approval by the Food and Drug Administration (FDA) to treat some patients with locally advanced or metastatic urothelial carcinoma.

Sponsored Content: Grandmother With Advanced Bladder Cancer Finds Hope When Options Were Limited

May 17th 2017

Bladder cancer is the sixth most common cancer in the U.S.

FDA Approves Bavencio for Bladder Cancer

May 9th 2017

The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

FDA Approves Imfinzi for Bladder Cancer

May 1st 2017

The Food and Drug Administration has granted accelerated approval for durvalumab for treatment of patients with bladder cancer.

Tecentriq Approved as First-Line Treatment for Some Patients With Bladder Cancer

April 18th 2017

The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.

The Future of Immunotherapy for Urothelial Carcinoma Treatment

April 7th 2017

In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.

Advancing Immunotherapy Impact in Bladder Cancer

March 17th 2017

In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.

My New Life With Cancer

March 13th 2017

Immunotherapy Is Moving Forward in Bladder and Other GU Cancers

March 9th 2017

Charles Drake, M.D., Ph.D.. is optimistic about immunotherapy as it continues to move toward the frontline setting in GU cancers.

Avelumab Granted Priority Review by the FDA for Metastatic Urothelial Carcinoma

February 28th 2017

The FDA granted avelumab a priority review to a biologics license application to treat some patients with metastatic urothelial carcinoma, according to the developers of the drug.

Combination Regimen Benefits Genitourinary Cancers

February 25th 2017

Cabometyx combinations showed activity in patients with GU cancers, according to a preliminary clinical study.

Immunotherapy Duo Trumps Single Agent in Metastatic Bladder Cancer

February 23rd 2017

Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.

New Treatment Options Offer Hope in Bladder Cancer

February 21st 2017

Checkpoint inhibitors drastically changed the treatment landscape of urothelial carcinoma, and more changes are on the way.

Keytruda Granted Priority Review for Treatment of Urothelial Carcinoma

February 6th 2017

The FDA granted Keytruda a priority review for the treatment of some patients with urothelial carcinoma.

Opdivo Is Approved for Urothelial Carcinoma Subset

February 3rd 2017

Opdivo was granted an accelerated approval for a subset of patients with urothelial carcinoma.

A New Standard of Care for Advanced Urothelial Carcinoma

February 2nd 2017

After results from a phase 3 trial showed that Keytruda improved overall survival, it may become the next standard of care for patients with advanced urothelial carcinoma.

Antidiabetic Agent Linked to Increased Risk of Bladder Cancer

January 18th 2017

The FDA recently issued a warning that a type of medicine used to treat Type 2 diabetes may increase a person's risk for developing bladder cancer.

Tecentriq Gets FDA Priority Review for New Use In Bladder Cancer

January 10th 2017

Tecentriq (atezolizumab) is being reviewed for the use in additional settings to treat bladder cancer.

FDA Grants Durvalumab Priority Review for Bladder Cancer

December 31st 2016

The PD-L1 inhibitor durvalumab was granted a priority review for the treatment of some patients with urothelial carcinoma.

In the Age of Immunotherapy, Chemotherapy Is Still a Mainstay for Bladder Cancer

December 16th 2016

As immunotherapy's potential continues to grow in the treatment of bladder cancer, Gopa Iyer, M.D., says that more research needs to be done before it becomes the next new standard.